Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA1274 | CA3059 | U.S. | 1997 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 187 |
| 2 | AZT+DDC+SQV | 100 |
| 3 | 3TC+DDI | 20 |
| 4 | 3TC+D4T+IDV | 23 |
| 5 | DDC+RTV+SQV | 20 |
| 6 | AZT+DLV+NFV+SQV | 11 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| L90M | Q58E, G73S | L10I, I15V, K20M, M36I, I62V, L63P |
| >CA3059| codons 1-99 PQITLWQRPIVTIKVGGQLMEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVREYD QVPIEICGHKAISTVLVGPTPVNIIGRNLMTQIGCTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| D67N, K70GR, T215F | K219Q | K103N | K102Q, K122E, I135V, D177X, G196E, I202X, E248D, A272G |
| >CA3060| codons 1-287 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV FAIKKKNSTGWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPXIVI YQYMDDLYVGSDLEIEQHRTKXEELRQHLLRWGFFTPDQKHQKEPPFLWMGYELHPDKWT VQPIVLPDKDSWTVNDIQKLVGKLNWASQIYGGIKVKQLCKLLRGTK |
References
| Author | Title | Citation |
| Shulman, NS | Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. | JAIDS, 2000 |
| Kantor, R | Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. | AAC, 2002 |
| Gonzales, MJ | HIV-1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. | J Infect Dis, 2001 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |